Cargando…
Cancer drug design and discovery /
The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Academic Press,
2008.
|
| Edición: | 1st ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn228148277 | ||
| 003 | OCoLC | ||
| 005 | 20231117015109.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 080516s2007 enkaf ob 001 0 eng d | ||
| 040 | |a OPELS |b eng |e pn |c OPELS |d OCLCQ |d OCLCF |d CHVBK |d OCLCQ |d OCLCO |d D6H |d OCLCO |d OCLCA |d OCLCQ |d LEAUB |d OCLCO |d OCLCA |d S2H |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCL |d OCLCO | ||
| 020 | |a 9780123694485 | ||
| 020 | |a 0123694485 | ||
| 035 | |a (OCoLC)228148277 | ||
| 050 | 4 | |a RS431.A64 |b C36 2008eb | |
| 060 | 4 | |a 2008 A-287 | |
| 060 | 4 | |a QV 269 |b N397c 2008 | |
| 082 | 0 | 4 | |a 616.994061 |2 22 |
| 245 | 0 | 0 | |a Cancer drug design and discovery / |c edited by Stephen Neidle. |
| 250 | |a 1st ed. | ||
| 260 | |a New York, NY : |b Academic Press, |c 2008. | ||
| 300 | |a 1 online resource (xv, 473 pages, 27 unnumbered pages of plates) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories. | ||
| 505 | 0 | |a Section I. Basic Principles -- 1. Modern cancer drug discovery: Integrating targets, technologies and treatments -- 2. Preclinical pharmacology and in vivo models -- 3. Clinical trial designs for more rapid proof-of-principle and approval -- Section II. Methodology -- 4. Structural biology and anticancer drug design -- 5. Natural product chemistry and cancer drug discovery -- 6. Pharmacokinetics & ADME optimization in drug discovery -- Section III. Drugs in the clinic and laboratory -- 7. Temozolomide: from cytotoxic to molecularly-targeted agent -- 8. Camptothecins for drug design, cancer cell death and gene targeting -- 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer -- Section IV. New Agents -- 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery -- 11. Cell cycle inhibitors in cancer: current status and future directions -- 12. Inhibition of DNA repair as a therapeutic target -- 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways -- 14. Heat shock protein-90-directed therapeutics and target validation -- 15. Inhibitors of tumour angiogenesis -- 16. The biology and oncology of RAFERK signalling P53 as a therapeutic target -- Section V. The reality of cancer drugs in the clinic -- 17. Cancer drug resistance -- 18. Failure Modes in Anticancer Drug Discovery and Development. | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a Antineoplastic agents |x Development. | |
| 650 | 0 | |a Antineoplastic agents |x Design. | |
| 650 | 0 | |a Cancer |x Chemotherapy. | |
| 650 | 0 | |a Antineoplastic agents. | |
| 650 | 0 | |a Antimitotic agents. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 1 | 2 | |a Antineoplastic Agents |0 (DNLM)D000970 |
| 650 | 2 | 2 | |a Drug Design |0 (DNLM)D015195 |
| 650 | 2 | 2 | |a Neoplasms |x drug therapy |0 (DNLM)D009369Q000188 |
| 650 | 2 | |a Antimitotic Agents |0 (DNLM)D050256 | |
| 650 | 6 | |a Cancer |x Chimioth�erapie. |0 (CaQQLa)201-0004691 | |
| 650 | 6 | |a Anticanc�ereux. |0 (CaQQLa)201-0004692 | |
| 650 | 6 | |a M�edicaments |x Conception. |0 (CaQQLa)201-0203461 | |
| 650 | 7 | |a Drugs |x Design |2 fast |0 (OCoLC)fst00898790 | |
| 650 | 7 | |a Antineoplastic agents |2 fast |0 (OCoLC)fst00810595 | |
| 650 | 7 | |a Antimitotic agents |2 fast |0 (OCoLC)fst00810570 | |
| 650 | 7 | |a Antineoplastic agents |x Design |2 fast |0 (OCoLC)fst00810598 | |
| 650 | 7 | |a Antineoplastic agents |x Development |2 fast |0 (OCoLC)fst00810599 | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast |0 (OCoLC)fst00845327 | |
| 650 | 7 | |a Cytostatikum |2 gnd |0 (DE-588)4068347-3 | |
| 650 | 7 | |a Krebsforschung |2 gnd |0 (DE-588)4165564-3 | |
| 700 | 1 | |a Neidle, Stephen. | |
| 776 | 0 | 8 | |i Print version: |t Cancer drug design and discovery. |b 1st ed. |d New York, NY : Academic Press, 2008 |z 9780123694485 |z 0123694485 |w (OCoLC)154760280 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780123694485 |z Texto completo |